New England Journal of Medicine February 10, 2022

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal, Monica M. Gomes da Silva, Dany B. Musungaie, et al.

Bottom Line

In unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19 and at least one risk factor for severe disease, a 5-day course of the oral antiviral molnupiravir initiated within 5 days of symptom onset significantly reduced the risk of hospitalization or death by day 29.

Key Findings

1. In the analysis of all randomized participants, hospitalization or death through day 29 occurred in 6.8% (48 of 709) of patients in the molnupiravir group compared to 9.7% (68 of 699) in the placebo group, representing an absolute risk reduction of 3.0 percentage points (95% CI, -5.9 to -0.1).
2. Through day 29, there was 1 death reported in the molnupiravir group (0.1%) compared to 9 deaths in the placebo group (1.3%).
3. An interim analysis at 50% enrollment (which led to early termination of the trial) showed a more pronounced effect size, with a 7.3% event rate for molnupiravir versus 14.1% for placebo (difference of -6.8 percentage points; P=0.001), but this efficacy attenuated in the full cohort analysis.
4. The incidence of adverse events was similar between the treatment arms, occurring in 30.4% of participants in the molnupiravir group and 33.0% in the placebo group.
5. The most commonly reported adverse events included diarrhea, nausea, and dizziness.
6. Subgroup analyses suggested diminished or no benefit in patients with evidence of prior SARS-CoV-2 infection, low baseline viral load, or diabetes.

Study Design

Design
RCT
Double-Blind
Sample
1,433
Patients
Duration
29 days
Median
Setting
Multicenter, global
Population Nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed COVID-19 within 5 days of symptom onset and at least one risk factor for severe illness.
Intervention Molnupiravir 800 mg orally twice daily for 5 days.
Comparator Matching placebo orally twice daily for 5 days.
Outcome Incidence of hospitalization for any cause or death through day 29.

Study Limitations

The trial exclusively enrolled unvaccinated individuals, limiting the generalizability of the findings to populations with high rates of natural or vaccine-induced immunity (as later demonstrated by the PANORAMIC trial).
Pregnant patients were excluded due to theoretical embryo-fetal toxicity risks associated with molnupiravir's mechanism of viral mutagenesis.
There was an unexplained, marked attenuation of the treatment effect between the interim analysis cohort and the cohort enrolled in the second half of the trial.
Molnupiravir was compared only to placebo and not evaluated against or in combination with other active COVID-19 therapeutics (such as monoclonal antibodies or nirmatrelvir/ritonavir).

Clinical Significance

The MOVe-OUT trial provided the foundation for the FDA Emergency Use Authorization (EUA) of molnupiravir as an early oral antiviral treatment for nonhospitalized patients with COVID-19 at high risk of disease progression. While its overall relative risk reduction of approximately 30% was lower than that of nirmatrelvir/ritonavir (Paxlovid, ~89%), molnupiravir offered a critical alternative oral treatment for patients who had contraindications to Paxlovid (e.g., complex drug-drug interactions or severe renal/hepatic impairment). Due to its modest efficacy and theoretical mutagenic risks, clinical guidelines generally positioned molnupiravir as an alternative, rather than a first-line, therapeutic option.

Historical Context

During the delta variant surge in late 2021, healthcare systems faced a dire need for easily administrable oral antivirals to prevent COVID-19 progression in outpatients. At the time, highly effective monoclonal antibodies required logistical hurdles like intravenous infusions and were increasingly threatened by viral spike protein mutations. Molnupiravir, a ribonucleoside analog inducing viral RNA mutagenesis, was highly anticipated as a variant-agnostic oral treatment. Initial excitement peaked when the trial was halted early for overwhelming efficacy (an approximately 50% risk reduction). However, when final data encompassing all 1,433 randomized participants were submitted for regulatory review, the risk reduction unexpectedly shrank to approximately 30%. Subsequently, large pragmatic trials like PANORAMIC (conducted in highly vaccinated populations) demonstrated that molnupiravir did not significantly reduce hospitalization or death in contemporary real-world settings, though it did accelerate symptom resolution.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the mechanism of action of molnupiravir, and why is it referred to as causing 'viral error catastrophe'?

Key Response

Molnupiravir is a prodrug converted to a ribonucleoside analog. Viral RNA polymerase incorporates it into the nascent RNA strand, leading to an accumulation of transition mutations. When the mutation rate exceeds the virus's error threshold, it cannot replicate viable virions, a concept known as lethal mutagenesis or viral error catastrophe.

Resident
Resident

Based on the MOVe-OUT trial and current approvals, what are the primary indications and significant contraindications for prescribing molnupiravir to an outpatient with COVID-19 compared to Paxlovid?

Key Response

Molnupiravir is indicated for mild-to-moderate COVID-19 outpatients at high risk of severe disease within 5 days of onset. However, due to its mechanism of lethal mutagenesis, it is contraindicated in pregnancy and not authorized for patients under 18 due to bone and cartilage growth concerns. It is often used as a second-line option when Paxlovid is contraindicated due to drug-drug interactions.

Fellow
Fellow

The interim analysis of the MOVe-OUT trial showed a roughly 50 percent relative risk reduction in hospitalization or death, but the final analysis showed only about a 30 percent reduction. How should this discrepancy influence our interpretation of interim trial data in rapidly evolving pandemics?

Key Response

The drop in efficacy between the interim and final cohorts highlights the volatility of small sample sizes in interim analyses, the 'winner's curse' phenomenon, and potential shifts in variant prevalence during the trial. Fellows must recognize that early stoppage for efficacy can sometimes overestimate the true treatment effect, necessitating cautious clinical extrapolation.

Attending
Attending

Given that the MOVe-OUT trial excluded vaccinated patients, how do you incorporate molnupiravir into your practice for the heavily vaccinated but perhaps older or immunocompromised patient populations we see today?

Key Response

The MOVe-OUT trial established efficacy in a strictly unvaccinated population. In modern practice, attendings must weigh the extrapolation of this data to vaccinated individuals, especially since later trials like PANORAMIC showed no significant reduction in hospitalization or death in highly vaccinated cohorts, making molnupiravir a marginal choice primarily reserved for high-risk, Paxlovid-ineligible patients.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

How does the emergence of novel SARS-CoV-2 variants during a rolling enrollment period impact the statistical power and primary outcome analysis of the MOVe-OUT trial, and what adaptive design strategies could mitigate this?

Key Response

The viral landscape shifted significantly during MOVe-OUT, acting as an unmeasured temporal confounder that alters baseline event rates and treatment effect sizes. Researchers might advocate for adaptive trial designs or stratified randomization by circulating variant epochs to ensure that power calculations remain robust and that genotype-treatment interactions can be formally tested.

Journal Editor
Journal Editor

As a peer reviewer, how would you address the potential long-term public health risk of a mutagenic antiviral accelerating the emergence of heavily mutated, resistant SARS-CoV-2 variants, and what virological monitoring data should be mandated in the manuscript?

Key Response

A critical threat to the broader applicability of this drug is its mechanism of driving viral mutagenesis. A rigorous reviewer would demand genomic sequencing data from the trial's treatment failures to ensure that sub-lethal mutagenesis did not inadvertently spawn virologically viable, mutated escape variants, weighing individual benefit against population-level risks.

Guideline Committee
Guideline Committee

How does the modest efficacy and mutagenic mechanism of molnupiravir demonstrated in MOVe-OUT dictate its placement in the NIH and IDSA COVID-19 treatment guidelines, and what specific evidence level supports this tiered recommendation?

Key Response

Due to its lower efficacy (approximately 30 percent relative risk reduction) compared to nirmatrelvir/ritonavir and remdesivir, along with mutagenicity concerns, NIH and IDSA guidelines relegate molnupiravir to an alternative therapy. It is recommended (Level C-IIa in NIH guidelines) only when preferred therapies are not available, feasible, or clinically appropriate.

Clinical Landscape

Noteworthy Related Trials

2022

EPIC-HR Trial

n = 2246 · NEJM

Tested

Nirmatrelvir/Ritonavir (Paxlovid) orally

Population

Symptomatic, nonhospitalized adults with Covid-19 at high risk for progression

Comparator

Placebo

Endpoint

Covid-19-related hospitalization or death from any cause through day 28

Key result: Treatment with nirmatrelvir/ritonavir resulted in an 89% lower risk of progression to severe Covid-19 than placebo.
2022

PANORAMIC Trial

n = 25708 · Lancet

Tested

Molnupiravir orally plus usual care

Population

Highly vaccinated adults in the community with early Covid-19 at increased risk

Comparator

Usual care alone

Endpoint

All-cause hospitalization or death within 28 days

Key result: Molnupiravir did not reduce the frequency of hospitalizations or death among high-risk vaccinated adults, though it did speed subjective recovery.
2022

PINETREE Trial

n = 562 · NEJM

Tested

Intravenous Remdesivir for 3 days

Population

Nonhospitalized patients with Covid-19 at high risk for disease progression

Comparator

Placebo

Endpoint

Covid-19-related hospitalization or death from any cause by day 28

Key result: A 3-day course of remdesivir resulted in an 87 percent lower risk of hospitalization or death than placebo in early COVID-19.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis